title: VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
abstract: 17-Allylamino-17-demethoxy geldanamycin (17-AAG), an inhibitor of heat shock protein 90 (Hsp90) function, is being developed as antitumor drug in patients with breast cancer. However, water-insolubility and hepatotoxicity limit its use. The purpose of this study was to begin to address these issues by determining whether 17-AAG can be formulated in long-circulating (PEGylated), biocompatible and biodegradable sterically stabilized phospholipid nanomicelles (SSM) to which vasoactive intestinal peptide (VIP) was grafted as an active targeting moiety and, if so, whether these nanomicelles are cytotoxic to MCF-7 human breast cancer cells. We found that particle size of 17-AAG loaded in VIP surface-grafted SSM was 16+/-1 nm and drug content was 97+/-2% (300 microg/ml). Cytotoxicity of 17-AAG loaded in VIP surface-grafted SSM to MCF-7 cells was significantly higher than that of 17-AAG loaded in non-targeted SSM (p<0.05) and similar to that of 17-AAG dissolved in dimethylsulfoxide. Collectively, these data demonstrate that 17-AAG is solubilized at therapeutically relevant concentrations in actively targeted VIP surface-grafted SSM. Cytotoxicity of these nanomicelles to MCF-7 cells is retained implying high affinity VIP receptors overexpressed on these cells mediate, in part, their intracellular uptake thereby amplifying drug potency. We propose that 17-AAG loaded in VIP surface-grafted SSM should be further developed as actively targeted nanomedicine for breast cancer.
authors.affiliation: Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL 60612-4325, USA.
authors.forename: Hayat
authors.initials: H
authors.lastname: Onyüksel
authors.forename: Prem S
authors.initials: PS
authors.lastname: Mohanty
authors.forename: Israel
authors.initials: I
authors.lastname: Rubinstein
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D016227:Benzoquinones / Q000008:administration & dosage* / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D005260:Female; D005786:Gene Expression Regulation; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D047029:Lactams, Macrocyclic / Q000008:administration & dosage* / Q000737:chemistry; D008823:Micelles; D010316:Particle Size; D012995:Solubility; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D008823:Micelles; D014660:Vasoactive Intestinal Peptide; C112765:tanespimycin
references.citation: J Antibiot (Tokyo). 1970 Sep;23(9):442-7
references.pmid: 5459626
references.citation: Cancer Res. 1988 Sep 15;48(18):5079-83
references.pmid: 2842044
references.citation: Nanomedicine. 2005 Mar;1(1):77-84
references.pmid: 17292061
references.citation: Chem Biol Interact. 2008 Jan 30;171(2):190-4
references.pmid: 17499651
references.citation: Langmuir. 2005 Apr 12;21(8):3279-90
references.pmid: 15807565
references.citation: Int J Cancer. 1992 Jun 19;51(4):613-9
references.pmid: 1601523
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5410-7
references.pmid: 18048823
references.citation: Hum Exp Toxicol. 1996 Sep;15(9):751-85
references.pmid: 8880211
references.citation: Anticancer Drugs. 2004 Aug;15(7):651-62
references.pmid: 15269596
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: J Pharm Sci. 2004 Oct;93(10):2476-87
references.pmid: 15349957
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8
references.pmid: 8078881
references.citation: Ann N Y Acad Sci. 1996 Dec 26;805:753-9
references.pmid: 8993473
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1789-93
references.pmid: 17363534
references.citation: Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15
references.pmid: 8102012
references.citation: J Control Release. 2003 Aug 28;91(1-2):123-33
references.pmid: 12932644
references.citation: Pharm Res. 2003 Feb;20(2):297-302
references.pmid: 12636171
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1775-82
references.pmid: 17363532
references.citation: Cancer Lett. 2004 Apr 8;206(2):149-57
references.pmid: 15013520
references.citation: Expert Opin Biol Ther. 2002 Jan;2(1):3-24
references.pmid: 11772336
references.citation: J Control Release. 2001 Jul 6;74(1-3):129-34
references.pmid: 11489489
references.citation: Breast Dis. 2002;15:53-60
references.pmid: 15687645
references.citation: Curr Pharm Des. 2001 Jan;7(2):89-111
references.pmid: 11172702
references.citation: Nat Protoc. 2006;1(3):1112-6
references.pmid: 17406391